Cangrelor

High quality intermediates and drug substance, it is conformed to EP,ICH

Product Name: Cangrelor

Product Description:

Cangrelor is a potent and reversible P2Y12 receptor antagonist used as an antiplatelet agent in clinical settings. It is a small molecule that inhibits platelet aggregation, preventing the formation of blood clots. Cangrelor offers rapid onset and offset of action, making it particularly useful in situations where immediate antiplatelet effects are required. This medication is commonly used during percutaneous coronary intervention (PCI) procedures and in patients with acute coronary syndromes.

Key Features:

1. P2Y12 Receptor Antagonist: Cangrelor specifically targets and antagonizes the P2Y12 receptor on platelets, inhibiting the ADP-mediated platelet activation pathway. By blocking this receptor, it prevents platelet aggregation and reduces the risk of clot formation.

2.  

3. Rapid Onset and Offset of Action: Cangrelor exhibits a rapid onset of action, providing immediate antiplatelet effects upon administration. It also has a short half-life, allowing for a quick recovery of platelet function after discontinuation, minimizing the risk of bleeding complications.

4. Reversibility: Cangrelor's antiplatelet effects are reversible, enabling clinicians to quickly restore normal platelet function if necessary. This feature is particularly valuable in situations where urgent surgery or interventions may be required.

5.  

6. Intravenous Administration: Cangrelor is administered intravenously, allowing for precise dosing and rapid distribution throughout the body. This route of administration ensures efficient and consistent systemic effects.

Parameters:

Functions:

1. Antiplatelet Effects: Cangrelor inhibits platelet aggregation by antagonizing the P2Y12 receptor, reducing the risk of thrombotic events in patients with cardiovascular conditions.

2. Prevention of Clot Formation: By blocking the ADP-mediated platelet activation pathway, Cangrelor prevents the formation of blood clots, reducing the risk of myocardial infarction, stroke, and stent thrombosis.

3. Use in Percutaneous Coronary Intervention (PCI): Cangrelor is commonly used during PCI procedures to prevent clot formation and maintain vessel patency, reducing the risk of complications such as restenosis and acute stent thrombosis.

4. Management of Acute Coronary Syndromes: Cangrelor is employed in patients with acute coronary syndromes, including unstable angina and non-ST-segment elevation myocardial infarction, to prevent further clot formation and improve clinical outcomes.